UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): June 1, 2021
 
Pharma-Bio Serv, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
(State or other jurisdiction of incorporation)
 
000-50956
20-0653570
(Commission File Number)
(I.R.S. Employer Identification No.)
 
6 Road 696, Dorado, Puerto Rico
00646
(Address of principal executive offices)
(Zip Code)
 
(787) 278-2709
(Registrant’s telephone number, including area code)
 
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
  
Securities registered pursuant to Section 12(b) of the Act: None
 
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
 
 
 
 
 
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 

 
 
 
Item 5.07. Submission of Matters to a Vote of Security Holders.
 
On June 1, 2021, Pharma-Bio Serv, Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”). Below is a summary of the proposals and corresponding votes.
 
Kirk Michel and Dov Perlysky were elected as Class II directors to serve for a term until the 2024 Annual Meeting of Stockholders or until their successors are duly elected and qualified. Kirk Michel and Dov Perlysky received the following votes:
 
Nominee
For
Withheld
Kirk Michel
13,216,386
10
Dov Perlysky
13,216,386
10
 
There were 2,446,428 broker non-votes on this proposal.
 
The ratification of the selection of Crowe PR PSC as the Company's independent certified public accountants for the fiscal year ending October 31, 2021 received the following votes:
 
For
Against
Abstain
15,662,745
14
65
 
There were no broker non-votes on this proposal.
 

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
PHARMA-BIO SERV, INC.
 
 
 
 
 
Date: June 2, 2021
By:
/s/ Pedro J. Lasanta
 
 
 
Pedro J. Lasanta
 
 
 
Chief Financial Officer, Vice President
Finance and Administration and Secretary